A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia

Transfusion

Volumn 54, Issue 2, 2014, Pages 306-315

  Onken, Jane E ^b   Bregman, David B ^a   Harrington, Robert A ^a   Morris, David ^a   Acs, Peter ^a   Akright, Bruce ^a   Barish, Charles ^a   Bhaskar, Birbal S ^a   Smith Nguyen, Gioi N ^a   Butcher, Angelia ^a   Koch, Todd A ^a   Goodnough, Lawrence T ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADMINISTRATION, ORAL; ADULT; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; HEART DISEASES; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MALTOSE; MIDDLE AGED; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84894054748     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12289     Document Type: Article

References (16)

1. Brugnara C,. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003; 49: 1573-1578.
2. Crichton RR, Danielson BG, Geisser P,. Iron therapy with special emphasis on intravenous administration. Bremen, Germany: Uni-Med Verlag Ag; 2005.
3. Clark SF,. Iron deficiency anemia. Nutr Clin Pract 2008; 23: 128-141.
4. Ganz T,. Hepcidin and iron regulation, 10 years later. Blood 2011; 117: 4425-4433.
5. Lu M, Cohen MH, Rieves D, Pazdur R,. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010; 85: 315-319.
6. Lyseng-Williamson KA, Keating GM,. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009; 69: 739-756.
7. Breymann C, Gliga F, Bejenariu C, Strizhova N,. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101: 67-73.
8. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R,. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008; 199: 435.e1-4357.
9. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A,. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110 (2 Pt 1): 267-278; Erratum in: Obstet Gynecol 2008;111:996.
10. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT,. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719-2728.
11. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P,; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
12. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C,; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-53.e1-2.
13. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD,. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599-1607.
14. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB,. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
15. Wolf M, Koch TA, Bregman DB,. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013 Mar 16. doi: 10.1002/jbmr.1923 [Epub ahead of print].
16. Bregman DB, Morris D, Koch TA, He A, Goodnough LT,. Hepcidin levels predict non-responsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88: 97-101.